Postprandial changes in gastrointestinal function and transit in cystic fibrosis assessed by Magnetic Resonance Imaging-Reference-Cited by-同舟云学术

Postprandial changes in gastrointestinal function and transit in cystic fibrosis assessed by Magnetic Resonance Imaging

Published:2021-07 Issue:4 Volume:20 Page:591-597
ISSN:1569-1993
Container-title:Journal of Cystic Fibrosis
language:en
Short-container-title:Journal of Cystic Fibrosis

Author:

Ng Christabella^ORCID,Dellschaft Neele S.,Hoad Caroline L.,Marciani Luca,Ban Lu,Prayle Andrew P.^ORCID,Barr Helen L.,Jaudszus Anke^ORCID,Mainz Jochen G.,Spiller Robin C.,Gowland Penny,Major Giles,Smyth Alan R.^ORCID

Funder

Cystic Fibrosis Foundation

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Pediatrics, Perinatology and Child Health

Reference32 articles.

1. Cystic fibrosis;Elborn;Lancet,2016

2. Cystic Fibrosis Foundation. Patient registry annual report. 2018.

3. UK Cystic Fibrosis Registry. Annual data report2018. 2019.

4. The top 10 reserach priorities in cystic fibrosis developed by a partnership between people with CF and healthcare providers;Rowbotham;Thorax,2018

5. A high prevalence of chronic gastrointestinal symptoms in adults with cystic fibrosis is detected using tools already validated in other GI disorders;Hayee;United Eur Gastroenterol J,2019

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A longitudinal study assessing the impact of elexacaftor/tezacaftor/ivacaftor on gut transit and function in people with cystic fibrosis using magnetic resonance imaging (MRI);Journal of Cystic Fibrosis;2024-09

2. Impact of extended Elexacaftor/Tezacaftor/Ivacaftor therapy on the gut microbiome in cystic fibrosis;Journal of Cystic Fibrosis;2024-05

3. A randomised crossover trial of tezacaftor-ivacaftor for gut dysfunction in cystic fibrosis with magnetic resonance imaging (MRI) outcomes: a pilot study.;NIHR Open Research;2024-03-19

4. Scoring Abdominal Symptoms in People with Cystic Fibrosis;Journal of Clinical Medicine;2024-03-13

5. Impact of extended Elexacaftor/Tezacaftor/Ivacaftor therapy on the gut microbiome in cystic fibrosis;2024-02-01